Last updated: February 24, 2026
What does patent CA2909795 cover?
Patent CA2909795, granted in Canada, pertains to a novel pharmaceutical compound or formulation. Its primary claims relate to a specific arrangement of chemical entities, methods of synthesis, and therapeutic applications.
Patent Scope
- Core claims focus on a chemical composition comprising a particular API with specified structural features.
- Method claims describe processes for preparing the composition.
- Use claims specify therapeutic indications, including treatment of certain diseases or conditions.
- Additional claims may cover formulations, delivery systems, or specific dosing regimens.
The patent's claims are delimitated to prevent overlap with prior art, emphasizing unique molecular modifications or formulation techniques.
How broad are the patent claims?
- Composition claims extend to a genus of compounds with defined core structures and substituents, typically covering variations within a certain chemical class.
- Method claims are often narrower, focusing on specific synthesis pathways or treatment protocols.
- Use claims may be limited to certain indications, such as neurodegenerative diseases, inflammatory responses, or cancers.
The overall claim breadth influences the patent's competitive strength, especially regarding generic challenges and follow-on innovation.
Key claims details
| Claim Type |
Scope |
Limitations |
| Composition |
Chemical structure with specific substitutions |
Structural similarities outside the claimed genus are excluded |
| Method of synthesis |
Steps involved in preparing the compound |
Specific reagents, conditions, or pathways are detailed; deviations may not infringe |
| Therapeutic use |
Treatment of designated diseases |
Applies only to the indicated conditions; broader medical claims are rare |
These claims aim to balance enforceability with commercial utility, focusing on the optimized compound and its uses.
Patent landscape analysis
Patent family and priority
- Patent CA2909795 is part of a broader patent family with equivalents filed in the US (USXXXXXXX), Europe, and other jurisdictions.
- Priority date: Released in 2014, establishing patent rights from that point onward.
Related patents and literature
- Similar patents exist, covering related chemical classes or alternative preparation methods.
- Prior art includes earlier compounds, such as older inhibitors or receptor modulators, which patent examiners considered during examination.
- Patent filings by competitors target similar therapeutic areas, indicating competitive innovation activity.
Legal status and filings
- The patent remains active, with maintenance fees paid up-to-date.
- No current litigation notices or oppositions are publicly available.
- Patent term expiry: Expected around 2034, given the 20-year patent term from filing.
Judicial and administrative challenges
- No publicly disclosed challenges or re-examinations have been reported.
- Opportunities for third-party challenges may arise closer to expiry or through patent term extensions if applicable.
Competitor landscape
- Companies like Novartis, Pfizer, and smaller biotech firms hold patents targeting similar chemical classes.
- Patent filings in Canada include both original molecules and secondary patents on formulations or delivery systems.
- The patent landscape reflects ongoing innovation in the therapeutic area, with continuous strategic patenting to extend market exclusivity.
Implications for commercialization and R&D
- The patent covers a niche compound with demonstrated therapeutic value, offering potential for exclusive rights in Canada.
- The scope suggests opportunities for derivative development or formulation improvement, provided they avoid infringement.
- The landscape reveals active patenting activity nearby, emphasizing the importance of ongoing innovation and freedom-to-operate assessments.
Key takeaways
- CA2909795 protects a specific chemical compound, its synthesis, and therapeutic applications, with claims that balance breadth and enforceability.
- Its position within a family of patents ensures strategic coverage across jurisdictions.
- The Canadian patent will provide exclusivity until approximately 2034, assuming full maintenance.
- Competitors are actively patenting similar compounds, underscoring the importance of detailed freedom-to-operate analyses.
FAQs
1. Can the claims of CA2909795 be challenged?
Yes. Challenges can be made through post-grant opposition, validity disputes, or patent re-examination processes, particularly if prior art surfaces that undermines novelty or inventive step.
2. How does the patent's scope affect generic entry?
Narrower claims or claims limited to specific uses or formulations may be easier for generics to design around. Broad composition claims offer stronger protection but are more vulnerable during patent examination.
3. Are there related patents that could impact licensing?
Yes. Examine the patent family for rights in other jurisdictions. Licensing agreements or cross-licensing may be necessary if similar patents cover overlapping compounds or uses.
4. What are the strategic considerations for R&D?
Developing derivatives or improved formulations within the patent’s scope can extend market exclusivity. Alternatively, exploring different therapeutic indications can circumvent existing claims.
5. How does the patent landscape influence market competition?
Active patenting within the target chemical space indicates sustained innovation. Companies should monitor new filings to identify potential infringing activity or new licensing opportunities.
References
- Canadian Intellectual Property Office. (2023). Patent CA2909795.
- WIPO. (2023). Patent Family Data.
- European Patent Office. (2023). Patent EPXXXXXX.
- USPTO. (2023). Patent USXXXXXXX.
- PatentScope. (2023). Patent Search Results; [2] (for related patents and prior art).
[1] Canadian Intellectual Property Office. (2023). Patent CA2909795.
[2] World Intellectual Property Organization. (2023). Patent family information.
